[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340121-105":59,"doc-detail-340121-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","navigating-precision-the-crucial-role-of-next-generation-sequencing-recurrence-risk-assessment-in-tailoring-adjuvant-therapy-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor2-negative-early-breast-cancer","Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer","","Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most common subtype, accounting for over two-thirds of new diagnoses. Adjuvant therapy is standard for early-stage disease, yet treatment optimization is needed to reduce unnecessary toxicity while addressing biological heterogeneity. The review highlights using biomarkers and gene expression assays, including Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict, to refine recurrence risk assessment and guide adjuvant chemotherapy selection. It also examines liquid biopsies, late relapse risk, and possible advantages of extended systemic therapy to personalize management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/navigating-precision-the-crucial-role-of-next-generation-sequencing-recurrence-risk-assessment-in-tailoring-adjuvant-therapy-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor2-negative-early-breast-cancer/340121/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/navigating-precision-the-crucial-role-of-next-generation-sequencing-recurrence-risk-assessment-in-tailoring-adjuvant-therapy-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor2-negative-early-breast-cancer/340121.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is optimizing adjuvant therapy important for HR+/HER2− early breast cancer?","Question",{"text":112,"@type":113},"Adjuvant therapy is standard, but patients show biological variability. Optimization helps minimize unnecessary side effects while still addressing recurrence risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genomic tests does the review discuss for tailoring adjuvant therapy?",{"text":117,"@type":113},"The review reviews evidence for Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict to refine recurrence risk assessment and treatment selection.",{"name":119,"@type":110,"acceptedAnswer":120},"How can gene expression assays support chemotherapy decisions?",{"text":121,"@type":113},"Gene expression assays can identify patients unlikely to benefit from adjuvant chemotherapy. This refines treatment strategies and avoids overtreatment when endocrine therapy alone may be sufficient.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340121,1790640549,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","CANCER BIOLOGY & THERAPY  \n2024, VOL. 25, NO. 1, 2405060 [https://doi.org/10.1080/15384047.2024.2405060](https://doi.org/10.1080/15384047.2024.2405060)  \nREVIEW  \nNavigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer  \nYing Xua*, Yingxue Qib*, Zhongyu Lub, Yuan Tanb, Dongsheng Chenb,c,d, and Haijun Luo e  \naDepartment of Obestetrics and Gynecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China; bThe Medical Department, Jiangsu Simcere Diagnostics Co. Ltd. Nanjing Simcere Medical Laboratory Science Co. Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China; cCancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China; dCenter of Translational Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China; eDepartment of Pathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China  \nABSTRACT  \nHormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most common subtype, representing over two-thirds of new diagnoses. Adjuvant therapy, which encompasses various medications and treatment durations, is the standard approach for managing early stage HR+ HER2-breast cancer. Optimizing treatment is essential to minimize unnecessary side effects while addressing the biological variability inherent in HR+/HER2− breast cancers. Incorporating biological biomarkers into treatment decisions, alongside traditional clinical factors, is vital. Gene expression assays can identify patients unlikely to benefit from adjuvant chemotherapy, thereby refining treatment strategies and improving risk assessment. This paper reviews evidence for several genomic tests, including Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict, which assist in tailoring adjuvant therapy. Additionally, we explore the role of liquid biopsies in personalizing treatment, emphasizing the importance of considering late relapse risks and potential benefits of extended systemic therapy for HR+/HER2− breast cancer patients.  \nARTICLE HISTORY  \nReceived 22 July 2024 Revised 2 September 2024 Accepted 12 September 2024  \nKEYWORDS  \nEarly breast cancer; HRpositive; HER2-negative; adjuvant therapy; recurrence risk assessment  \nIntroduction  \nBreast cancer (BC) is one of the most common cancers in women worldwide. It is highly heterogeneous and the various BC types differ from each other both morphologically and molecularly. Several known and unknown factors influence treatment response and the risk of relapse. 1–3 Hormone receptor-positive (HR+) BC is a hormone-dependent tumor. Of the 300,000 patients diagnosed with breast cancer in 2023,4 approximately 190,000 were identified with early-stage HRpositive disease. HR+ BC progresses more slowly and has a better overall prognosis and longer survival period than certain other BC subtypes. The advantages of adjuvant chemotherapy in individuals diagnosed with HR+ BC early-stage breast cancer should be carefully weighed against its potential short- and long-term negative consequences. It is crucial to identify the specific patient population who are most likely to derive significant clinical benefits from chemotherapy. Endocrine therapy (ET) is one of the first targeted anticancer therapies to be clinically administered.5,6 Endocrine agents are the mainstay of early-stage ER+/HER2-BC treatment. Several large clinical trials demonstrated that 5 years of adjuvant hormonal therapy significantly reduces the risks of local  \nrecurrence, contralateral BC, distant recurrence, and death inpatients with HR+ early-stage BC.7,8 Clinical trial data for patients with early-stage HR+/HER2-BC showed that com","cbCaia5jqoeo4brW","https://ap.wps.com/l/cbCaia5jqoeo4brW","pdf",426148,"English","# Introduction\n## Hormone receptor-positive breast cancer and heterogeneity\n## Adjuvant therapy benefits and need for optimization\n## Biomarkers and genomic assays for recurrence risk\n## Liquid biopsies and personalization of treatment","[{\"question\":\"Why is optimizing adjuvant therapy important for HR+/HER2− early breast cancer?\",\"answer\":\"Adjuvant therapy is standard, but patients show biological variability. Optimization helps minimize unnecessary side effects while still addressing recurrence risk.\"},{\"question\":\"Which genomic tests does the review discuss for tailoring adjuvant therapy?\",\"answer\":\"The review reviews evidence for Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict to refine recurrence risk assessment and treatment selection.\"},{\"question\":\"How can gene expression assays support chemotherapy decisions?\",\"answer\":\"Gene expression assays can identify patients unlikely to benefit from adjuvant chemotherapy. This refines treatment strategies and avoids overtreatment when endocrine therapy alone may be sufficient.\"}]","Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer | PDF",1790034292,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93c34eaaef887b85bfb7014eca7fb9ec.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c66b41190a9cacb4b376e35faad88df0.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/329ba682f4547900982021c3b215c9cc.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd8d2bf432644e02ca4d96afd2eda82f.webp",980,1276]